Thu, Dec 18, 2014, 2:28 AM EST - U.S. Markets open in 7 hrs 2 mins

Recent

% | $
Quotes you view appear here for quick access.

Stereotaxis Inc. Message Board

arfarfman 21 posts  |  Last Activity: Dec 16, 2014 11:40 AM Member since: Nov 28, 2007
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • arfarfman arfarfman Dec 16, 2014 11:40 AM Flag

    thats because it's still the beginning... wait until 2015 when GTX gives us some solid direction and results

    Sentiment: Hold

  • arfarfman arfarfman Dec 15, 2014 10:20 AM Flag

    you beat me:) at $2.00 thats 50k not too shabby. it'll get there again one day. GL

    Sentiment: Hold

  • arfarfman arfarfman Dec 15, 2014 8:24 AM Flag

    How did you miss the boat?? we've been talking about this between .40-.50 for months! I know you have a nice chunk of shares right??

    Sentiment: Hold

  • Reply to

    Needs a R/S

    by who_gnu_1235 Dec 14, 2014 1:30 PM
    arfarfman arfarfman Dec 15, 2014 8:22 AM Flag

    R/S makes no sense. we just had funding into 2016. This will be over $2.00 easy soon enough. GTX is getgetting back on track, my advice stay in and hold.

    Sentiment: Buy

  • arfarfman arfarfman Dec 4, 2014 8:53 AM Flag

    Well jimmeycrackcorn. anything is possible.. insider support and these big acquisition of shares down here lead me to believe a few things. 1- no reverse split in the plans, that means they're hoping they will regain compliance which means over $1.00--Otherwise why not have reverse split already, then dilute to raise additional cash? (This is great news) 2-comparitively GTX is no further along then some other bios that are 2,3,4,5 times the price right now. I think GTX will return to fair value around $2.00 with some decent news- not sure when exactly, but when it does happen it will be fairly quickly within a few days I think.

    I have bought and sold Ariad (ARIA) for years. In around 2000 or so they were about .70, with no cancer drug, nothing exciting but the insiders supported and eventually brought a drug to market, with multiple indications. it went into the 20's in the years that followed... ARIA was counted out back then as a worthless company, the same could be say for many. Fact is we don't know, this is speculative, but I'm hopeful and investing a little here and there to see how this one turns out.

    Sentiment: Buy

  • arfarfman arfarfman Dec 3, 2014 11:53 AM Flag

    12K shares so far. I would like to get to 20k but we will see

    Sentiment: Buy

  • arfarfman arfarfman Dec 3, 2014 10:43 AM Flag

    yes. cost avg .53 and will continue to buy as I can afford too. looking for some nice updates in 2015

    Sentiment: Buy

  • arfarfman arfarfman Nov 19, 2014 2:24 PM Flag

    I'm with you. Hyde added 24Million shares at .65 wow! GTX alive and well, will move big 2015 imo

    Sentiment: Strong Buy

  • Reply to

    All quiet on the western front

    by auburndale303 Oct 30, 2014 4:25 PM
    arfarfman arfarfman Oct 31, 2014 8:29 AM Flag

    $2+ bucks in 1st-2nd QTR 2015, dug deep here with research and conclude there will be definitive news after a much needed quiet shuffle and re-organization. Anticipate new data, Capesaris is exciting, strong insider support still. I'm holding some GTX, bought it all under .60, not much, but enough:)

    Sentiment: Buy

  • arfarfman arfarfman Oct 22, 2014 6:41 AM Flag

    Yes this is really interesting and definitely not something I picked up on researching GTX. This article suggests using SERMs FDA approved drugs to battle Ebola and other viruses. It is all about teremifene which GTX owns exclusive rights and patents too, combined with clomiphene, looks like they have evaluated its use against Ebola strains...

    the ER antagonists clomiphene and toremifene are FDA-approved drugs with oral availability, good safety, and tolerability profiles and a long history of use. These drugs have good plasma exposure and bioavailability, making them excellent candidates for repurposing efforts for use for the treatment of Ebola virus infection (11, 12)

    The qRT-PCR results confirmed that clomiphene and toremifene were active against the native Ebola virus species as well as MARV...

    ????????

  • GTXI "This is the company i was referring to earlier today along with a brief snyopsis as to why i thought it could be a good, speculative investment. Have at it gentlemen:

    The ebola virus is taking the media by storm - perhaps for good reason or the case can be made that such hysteria is overhyped. In any event, investments should be pouring into this epidemic and i recently came across an article(http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955358/) that linked selective estrogen receptive modulators inhibited the ebola virus. Moreso, select SERMs were granted FDA approval (clomidphene & toremifene). After some due diligence, all manufactures of Clomidphene (commonly in the phx form of clomid) were produced by private companies. To capitalize off this, one would need to do an M&A analysis and have enough dry powder to make a few investments into potential acquirers. With this said, there is another option, to play the toremifene SERM through a penny stock (though trading still on NASDAQ) called GTX, inc or ticker GTXI. This company has exclusive rights to sell toremifene in the US (http://phx.corporate-ir.net/phoenix.zhtml?c=148196&p=irol-newsArticle_print&ID=658317&highlight=) and also appear to be undertaking a huge correction (more research needs to be conducted on this).


    The second reason i think it may be a good speculation relates to their delisting on 10.3. In accordance with NASDAQ rules, a company must maintain a market cap of 5mm (no problem here) along with a min share price of $1.00. GTXI has 180 days to regain the latter or it will be delisted. With respect to delisted companies, it can expedite a sell off because institutional investors cannot hold such companies and often times creditors will call in their loans exacerbating the problem. In this case, they have no debt and institutional investors repre

  • arfarfman arfarfman Oct 21, 2014 6:59 AM Flag

    this was stated in August regarding Capesaris:
    "Enrollment in the 125 mg arm has been completed without any incidences of venous thromboembolic events (VTEs) and, after a pre-specified safety review by the independent Data Safety Monitoring Board, the Company is now enrolling subjects in the 250 mg arm. Based upon the observed safety and efficacy in the 125 mg arm and with no safety issues having been observed in the first ten metastatic patients enrolled in the 250 mg arm, the Company is enrolling the remainder of the 250 mg arm with both high risk non-metastatic and metastatic CRPC patients, with the expectation that enrollment will be completed later this year. Data from the study is expected during the first quarter of 2015. "

    Sentiment: Strong Buy

  • arfarfman arfarfman Oct 21, 2014 6:55 AM Flag

    marc450sl - you are right that the reporting from July to Oct 2014 does show Hydes position go from 18+million to 14+million, but I see no transaction reported for the sale. Either way he does still own over 14mill. If he sold at 1.25 that was a good bet, because this did just hit .40. Maybe he is going to add more now under a buck....? Either way Hanover the new interim CEO has been adding shares for the last few months. Not millions, but thousands, but its something. The issue is right now there is no volume, because investors have sold out and forgotten GTX, plus there has not been any solid news in a while. GTX has changed its direction and ownership, but it seems insiders are still supporting the company. If so this really is a quiet period, everything suggests they are still working at Capesaris, Enobosarm etc, so be patient for an update. If you are not sure, read up, there is plenty of reading out there and as recent as August they presented that they are still pursuing European regulatory path for Enobosarm and Capesaris results are due Q1 2015... GL

  • arfarfman arfarfman Oct 20, 2014 2:46 PM Flag

    interesting as of 10/1/14 it says he owns: 14,834,206 shares

  • arfarfman arfarfman Oct 20, 2014 9:56 AM Flag

    putting the pieces together!!

    In the 15 years since J.R. “Pitt” Hyde was diagnosed with prostate cancer, the founder of AutoZone Inc. (AZO) has devoted the largest single portion of his billion-dollar fortune to searching for a cure.

  • arfarfman arfarfman Oct 20, 2014 9:53 AM Flag

    in my opinion based on my research Hyde they are betting on Capesaris results.. read this. They are looking at 2015. I found this from 2011:

    “We think it has a better chance than maybe some other drugs in phase 3 clinical trials because it has actually worked in phase 2 so far,” said Nierengarten, who has an “outperform” rating on GTx with a 12-month target price of $13.

    Capesaris “is the first new hormone treatment for prostate cancer in quite some time,” Nierengarten said. “The current treatment options have a lot of side effects associated with them hopefully the GTx compound won’t have.”

    Even if the trials go well, Food and Drug Administration approval likely wouldn’t come for Ostarine until 2014 at the earliest and 2015 at the soonest for Capesaris, said Steiner, 50, who is GTx’s CEO.

    “All your risk and all your capital is front-end loaded unlike the retail business I grew up in where if you didn’t make money every quarter you were toast,” Hyde said. “You’ve got to take a long view in this business.”

    At yesterday’s close, Hyde’s stake in GTx was worth about $65 million.

    Sentiment: Strong Buy

  • Why?? now $.60... Can't be too happy, or are they looking at 2015?
    "On March 6, two significant investors profiled below, J.R. "Pitt" Hyde, III and O. Mason Hawkins, participated in a private placement of GTx common stock and purchased 11,976,048 shares of GTXI at $1.78/share. This purchase included warrants for each investor to purchase an additional 5,089,821 shares (10,179,642 total shares) at $1.67/share. Once the warrants are fully exercised, these two investors will have acquired 22,155,690 share of GTXI at an average price of $1.73, an investment of over $38 million."

  • gtx is still operating and soon to release Phase II trial results for metastatic cancer drug, Enobosarm. However the delay has caused a big sell off as these results were expected by the end of July... This has spooked everyone I guess because now it is now Oct with no word on anything lately. Anyone clued in here?

  • Reply to

    PPS is rising...Insiders are buying..

    by running2fall Oct 14, 2014 10:46 AM
    arfarfman arfarfman Oct 14, 2014 11:29 AM Flag

    I bought yesterday and this morning. only 10k but this is a long shot. I see someone has 200k+ on bid not too shabby. I believe this can turn. GTX is actively recruiting for 2 different studies. Capesaris new data available 1 QTR 2015. Worth keeping a little bit here so oversold.

  • arfarfman by arfarfman Oct 14, 2014 8:10 AM Flag

    I remember gtxi getting a lot of attention a few years ago. Whats the chances this does a kerx, mnkd chtp arna etc? still active on clincialtrials dot gov, chart is super oversold... is this one done?? these things have a funny way over turning around when you least expect it sometimes....

STXS
1.36+0.03(+2.26%)Dec 17 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.